EMA Restricts Rubraca’s Use Due To Concerns Over Benefit & Safety
Clovis Voluntarily Dropped Drug’s Third-Line Ovarian Cancer Indication In US
EU doctors are being told not to prescribe Rubraca as third-line treatment for cancers of the ovary, fallopian tubes or peritoneum with a BRCA mutation.
